{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:16:57Z","timestamp":1767903417840,"version":"3.49.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n T-type calcium channels, particularly the Cav3.2 subtype, are involved in pain transduction. Experimental studies and human data suggested that increased T-type channels activity or expression contributes to visceral hypersensitivity in irritable bowel syndrome (IBS), and that their inhibition alleviates pain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the therapeutic potential of ethosuximide, a T-type calcium channel blocker, for IBS-related abdominal pain.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This proof-of-concept, multicenter, double-blinded, placebo-controlled randomized clinical trial started in February 2018 and completed in February 2022, with analyses performed between October 2023 and December 2024. Participants were adults meeting Rome IV criteria for IBS, treated in 10 gastroenterology departments in French university hospitals, with abdominal pain intensity rated at least 4 out of 10 during a 7-day run-in period.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized to receive ethosuximide or placebo daily for 12 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the responder rate, defined as at least 30% reduction in mean abdominal pain intensity associated with a Subject Global Assessment of relief score at least 4 (ie, considerably or completely relieved). Secondary outcomes included safety, IBS symptom severity, and quality of life.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 161 enrolled patients, 124 were randomized (64 ethosuximide; 60 placebo). The mean (SD) age was 43.7 (14.9) years, 72 (58.1%) were women, the median (IQR) IBS duration was 5.0 (1.4-10.6) years, and the mean (SD) abdominal pain intensity was 6.0 (1.0). In the intent-to-treat analysis, responder rates did not differ significantly between groups (17 of 64 patients [26.6%] for ethosuximide vs 14 of 60 patients [23.3%] for placebo; relative risk, 1.14; 95% CI, 0.61-2.11). Ethosuximide was less well tolerated, with higher discontinuation rates (30 patients [46.9%] vs 13 patients [21.7%];\n P<\/jats:italic>\n \u2009=\u2009.003) and more adverse events (261 of 463 adverse events reported overall [56.4%] were determined to be caused by ethosuximide;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), most commonly headaches, sleep disturbances, and nausea, compared with placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, ethosuximide did not demonstrate efficacy over placebo for the treatment of IBS-related abdominal pain, and was associated with reduced tolerability. These findings do not support the use of ethosuximide for IBS pain management but highlight the need for development of more selective and better-tolerated T-type calcium channel modulators.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02973542<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.51368","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:00:42Z","timestamp":1767888042000},"page":"e2551368","source":"Crossref","is-referenced-by-count":0,"title":["Ethosuximide and Irritable Bowel Syndrome\u2013Related Abdominal Pain"],"prefix":"10.1001","volume":"9","author":[{"given":"Nicolas","family":"Kerckhove","sequence":"first","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne, INSERM, UMR 1107 \u2013 NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroent\u00e9rologie, Service de Pharmacologie M\u00e9dicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Zerbib","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Centre M\u00e9dico-chirurgical Magellan, H\u00f4pital Haut-L\u00e9v\u00eaque, Service de Gastroent\u00e9rologie, Universit\u00e9 de Bordeaux, INSERM CIC 1401, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Chambaz","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Rennes 1, CHU Rennes, INSERM U1073, Service de Gastroent\u00e9rologie, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mion","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Universit\u00e9 de Lyon, Labtau U 13032 Inserm, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Zalar","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Rouen Normandie, INSERM, ADEN UMR1073, \u201cNutrition, Inflammation and microbiota-gut-brain axis\u201d, CHU Rouen, CIC-CRB 1404, Service de Gastroent\u00e9rologie, Service de Physiologie, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Goutorbe","sequence":"additional","affiliation":[{"name":"CH Bayonne, Service de Gastroent\u00e9rologie, Bayonne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Coffin","sequence":"additional","affiliation":[{"name":"Assistance Publique- H\u00f4pitaux de Paris, Service d\u2019H\u00e9pato-Gastro-Ent\u00e9rologie, H\u00f4pital Louis Mourier, DMU ESPRIT AP-HP Nord, Colombes, France"},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, Centre de recherche sur l\u2019Inflammation, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Payen","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne, INSERM, UMR 1107 \u2013 NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroent\u00e9rologie, Service de Pharmacologie M\u00e9dicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Roman","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Universit\u00e9 de Lyon, Labtau U 13032 Inserm, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Guilngar","sequence":"additional","affiliation":[{"name":"CH Bayonne, Service de Gastroent\u00e9rologie, Bayonne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne, INSERM, UMR 1107 \u2013 NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroent\u00e9rologie, Service de Pharmacologie M\u00e9dicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dual\u00e9","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne, INSERM, UMR 1107 \u2013 NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroent\u00e9rologie, Service de Pharmacologie M\u00e9dicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Dapoigny","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne, INSERM, UMR 1107 \u2013 NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroent\u00e9rologie, Service de Pharmacologie M\u00e9dicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Melchior","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Rouen Normandie, INSERM, ADEN UMR1073, \u201cNutrition, Inflammation and microbiota-gut-brain axis\u201d, CHU Rouen, CIC-CRB 1404, Service de Gastroent\u00e9rologie, Service de Physiologie, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Scanzi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne, INSERM, UMR 1107 \u2013 NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroent\u00e9rologie, Service de Pharmacologie M\u00e9dicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France"},{"name":"CH Thiers, Service de Gastroent\u00e9rologie, Thiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"IBSET Investigator Group (IIG)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Vernon","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Hastier de Chelle","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Campos","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gine","family":"Truchi","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Vitton","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Gourcerol","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Sautel","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Jouet","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamila","family":"Lenz","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eymeric","family":"Chartrain","sequence":"additional","affiliation":[{"name":"for the IBSET Investigator Group (IIG)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"6","key":"zoi251367r1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction.","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"zoi251367r2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study.","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"zoi251367r3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","article-title":"Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.","volume":"5","author":"Oka","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"zoi251367r4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/MEG.0b013e3282f1621b","article-title":"Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.","volume":"19","author":"Brun-Strang","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"zoi251367r5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/gut.2007.140806","article-title":"Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.","volume":"58","author":"Piche","year":"2009","journal-title":"Gut"},{"key":"zoi251367r6","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.718356","article-title":"Inflammatory and microbiota-related regulation of the intestinal epithelial barrier.","volume":"8","author":"Barbara","year":"2021","journal-title":"Front Nutr"},{"issue":"1","key":"zoi251367r7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2982.2006.00875.x","article-title":"Mechanisms of hypersensitivity in IBS and functional disorders.","volume":"19","author":"Azpiroz","year":"2007","journal-title":"Neurogastroenterol Motil"},{"issue":"6","key":"zoi251367r8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.coph.2003.06.007","article-title":"Role of ion channels in mechanisms controlling gastrointestinal pain pathways.","volume":"3","author":"Cervero","year":"2003","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"zoi251367r9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1254\/jphs.13R05CP","article-title":"T-type calcium channels: functional regulation and implication in pain signaling.","volume":"122","author":"Sekiguchi","year":"2013","journal-title":"J Pharmacol Sci"},{"issue":"7","key":"zoi251367r10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00424-012-1211-y","article-title":"Neuropathic pain: role for presynaptic T-type channels in nociceptive signaling.","volume":"465","author":"Todorovic","year":"2013","journal-title":"Pflugers Arch"},{"issue":"27","key":"zoi251367r11","doi-asserted-by":"publisher","first-page":"11268","DOI":"10.1073\/pnas.1100869108","article-title":"T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome.","volume":"108","author":"Marger","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"zoi251367r12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/bph.14608","article-title":"Inhibition of Cav 3.2 calcium channels: a new target for colonic hypersensitivity associated with low-grade inflammation.","volume":"176","author":"Picard","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"11","key":"zoi251367r13","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1111\/nmo.12860","article-title":"Colonic overexpression of the T-type calcium channel Cav 3.2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients.","volume":"28","author":"Scanzi","year":"2016","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"zoi251367r14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/jcpt.13556","article-title":"Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to irritable bowel syndrome.","volume":"47","author":"El-Haggar","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"zoi251367r15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015380","article-title":"Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome\u2014IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial.","volume":"7","author":"Kerckhove","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"zoi251367r16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/ajg.2010.12","article-title":"Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.","volume":"105","author":"Trentacosti","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"zoi251367r17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The Irritable Bowel Severity Scoring System: a simple method of monitoring irritable bowel syndrome and its progress.","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"zoi251367r18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/bjs.1800820229","article-title":"Gastrointestinal Quality of Life Index: development, validation and application of a new instrument.","volume":"82","author":"Eypasch","year":"1995","journal-title":"Br J Surg"},{"issue":"2","key":"zoi251367r19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1524-4733.2006.00086.x","article-title":"Performance of the EQ-5D in patients with irritable bowel syndrome.","volume":"9","author":"Bushnell","year":"2006","journal-title":"Value Health"},{"issue":"2","key":"zoi251367r23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome.","volume":"32","author":"Ford","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"28","key":"zoi251367r24","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/sim.4102","article-title":"Adaptive increase in sample size when interim results are promising: a practical guide with examples.","volume":"30","author":"Mehta","year":"2011","journal-title":"Stat Med"},{"issue":"23","key":"zoi251367r25","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1002\/sim.1585","article-title":"Simple procedures for blinded sample size adjustment that do not affect the type I error rate.","volume":"22","author":"Kieser","year":"2003","journal-title":"Stat Med"},{"issue":"7","key":"zoi251367r26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data.","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"10","key":"zoi251367r27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/aje\/kwg074","article-title":"Estimating the relative risk in cohort studies and clinical trials of common outcomes.","volume":"157","author":"McNutt","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"4","key":"zoi251367r28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/aje\/kwh221","article-title":"Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies.","volume":"160","author":"Greenland","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"19","key":"zoi251367r29","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk: a method of correcting the odds ratio in cohort studies of common outcomes.","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"zoi251367r30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance.","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"issue":"1","key":"zoi251367r31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG clinical guideline: management of irritable bowel syndrome.","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"zoi251367r32","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.cgh.2021.07.006","article-title":"AGA clinical practice update on management of chronic gastrointestinal pain in disorders of gut-brain interaction: expert review.","volume":"19","author":"Keefer","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"zoi251367r33","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome.","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"},{"issue":"10414","key":"zoi251367r34","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)01523-4","article-title":"Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"402","author":"Ford","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"zoi251367r35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2169\/internalmedicine.52.9147","article-title":"A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome.","volume":"52","author":"Chao","year":"2013","journal-title":"Intern Med"},{"issue":"3","key":"zoi251367r36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/0049825021000061606","article-title":"Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes.","volume":"33","author":"Bachmann","year":"2003","journal-title":"Xenobiotica"},{"key":"zoi251367r20","unstructured":"Rome Foundation. Rome IV criteria. Accessed December 16, 2024. https:\/\/theromefoundation.org\/rome-iv\/rome-iv-criteria\/"},{"key":"zoi251367r21","unstructured":"European Medicines Agency. Clinical development of medicinal products intended for the treatment pain. September 17, 2018. Accessed May 5, 2022. https:\/\/www.ema.europa.eu\/en\/clinical-development-medicinal-products-intended-treatment-pain"},{"key":"zoi251367r22","unstructured":"European Medicines Agency. Evaluation of medicinal products for the treatment of irritable bowel syndrome\u2014scientific guideline. September 25, 2014. Accessed March 10, 2025. https:\/\/www.ema.europa.eu\/en\/evaluation-medicinal-products-treatment-irritable-bowel-syndrome-scientific-guideline"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843540\/kerckhove_2026_oi_251367_1767025248.1684.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:00:43Z","timestamp":1767888043000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843540"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.51368","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}